SinoCare Group

Sinocare Group was established in 2002 in Changsha, China, with a founding mission to make blood glucose monitoring accessible to every person with diabetes in China. The company began as a domestic manufacturer focused on biosensor technology for chronic disease management, particularly diabetes. In its early years, Sinocare obtained key regulatory certifications, including the medical device registration certificate and production approval in 2004, followed by ISO 13485 certification and CE marking in 2007. A major turning point in Sinocare’s development came in 2016, when it acquired two U.

S. -based companies: Nipro Diagnostics Inc. (renamed Trividia Health Inc. ) and PTS Diagnostics Inc.

Sinocare operates seven R&D centers and eight production bases worldwide. It serves over 25 million users across 135 countries and regions, and has become the largest blood glucose monitoring system (BGMS) manufacturer in China and the fourth largest globally. Sinocare is listed on the Shenzhen Stock Exchange under the stock code 300298. Sinocare’s product portfolio is centered on biosensor-based diagnostic tools for chronic disease management.

Its core offerings include blood glucose meters, continuous glucose monitoring systems (CGMS), and multi-function diagnostic devices. These products are designed for both individual users and healthcare institutions. The company’s blood glucose meters are available in various models, including dual-function and “three-in-one” systems that can simultaneously measure glucose, uric acid, and blood lipids. Sinocare also offers mobile and intelligent glucose meters that integrate with digital platforms for data tracking and analysis.

Beyond glucose monitoring, Sinocare has expanded into diagnostics for other chronic conditions. Its devices now support the measurement of blood pressure, cholesterol, uric acid, and homocysteine levels. These tools are part of a broader strategy to address the “five highs” of chronic disease: high blood glucose, high blood pressure, high cholesterol, high uric acid, and high homocysteine. In addition to hardware, Sinocare is developing digital health management solutions.

These include mobile applications and cloud-based platforms that collect, analyze, and visualize health data. The company is also exploring AI-driven tools for personalized disease management, aiming to integrate biosensors, the Internet of Things (IoT), and smart healthcare technologies into a unified ecosystem. Sinocare’s revenue is primarily derived from the sale of diagnostic devices and consumables. A key area of development is the integration of artificial intelligence into its product ecosystem.

Sinocare is working on expanding the capabilities of its AI platform, SinoGPT, to support real-time monitoring, predictive analytics, and personalized health recommendations for a range of chronic conditions.